Two GHRH analogs from different eras. Sermorelin is the original GHRH (1-29) fragment; CJC-1295 is the engineered, longer-acting evolution.
Sermorelin and CJC-1295 both engage the GHRH receptor — they are essentially the same lineage with different stability profiles. Sermorelin came first; CJC-1295 was engineered to overcome its short half-life.
| Sermorelin | CJC-1295 | |
|---|---|---|
| Class | GHRH (1-29) analog | Stabilized GHRH analog |
| Sequence length | 29 amino acids | 30 amino acids |
| Half-life | 10–20 minutes | ~30 minutes (no-DAC) / days (DAC) |
| Clinical track record | Decades | Newer, growing literature |
| Receptor | GHRH-R | GHRH-R |
Sermorelin is a 29-amino-acid GHRH analog representing the bioactive fragment of natural growth hormone–releasing hormone. It has one of the longest track records in clinical-research literature among GH-supporting peptides.
Activates pituitary GHRH receptors to stimulate natural GH secretion.
CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH). The no-DAC version produces a pulsatile GH release pattern and is frequently paired with a ghrelin-receptor peptide such as Ipamorelin in research protocols.
Binds the GHRH receptor on the pituitary to stimulate endogenous growth hormone release while preserving natural pulsatility.
If a research protocol prioritizes pulsatility and a long clinical pedigree, Sermorelin is the conservative pick. If it prioritizes a stronger single dose, CJC-1295 no-DAC tends to win on paper.
The table above compares published characteristics, not outcomes for any individual. Mechanism, half-life, and dosing cadence are properties of the molecule; response, tolerability, and suitability are properties of the person. Trial averages describe populations and say nothing definitive about a single case.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Both target the GHRH receptor. CJC-1295 is engineered for greater stability and longer action than the parent Sermorelin molecule.
They act on complementary pathways — CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin/GHS-R receptor — producing a stronger synergistic GH pulse in research models.
DAC (Drug Affinity Complex) extends half-life to several days for tonic GH elevation. No-DAC preserves natural pulsatility, which most research protocols prefer.